Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum

[1]  J. Hardy,et al.  Apolipoprotein E in Alzheimer's disease: an update. , 2014, Annual review of neuroscience.

[2]  A. Saykin,et al.  APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  A. Saykin,et al.  Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. , 2013, Annual review of clinical psychology.

[4]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[5]  W. M. van der Flier,et al.  Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia , 2013, Neurology.

[6]  D. Holtzman,et al.  Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.

[7]  Guojun Bu,et al.  Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[8]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[9]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[10]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[11]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[12]  S. Rapcsak,et al.  Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers , 2011, Neurology.

[13]  Daoqiang Zhang,et al.  Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.

[14]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[15]  Michael Weiner,et al.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.

[16]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[17]  Norbert Schuff,et al.  Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data , 2010, Alzheimer's & Dementia.

[18]  W. Chan,et al.  Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. , 2010, Archives of neurology.

[19]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[20]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[21]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[22]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[23]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[24]  et al.,et al.  Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2009, NeuroImage.

[25]  M Schwaiger,et al.  Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.

[26]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[27]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[28]  W. Jagust,et al.  Striatal dopamine and working memory. , 2009, Cerebral cortex.

[29]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[30]  Sid E O'Bryant,et al.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.

[31]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[32]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[33]  Gregory G. Brown,et al.  fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease , 2005, Neurology.

[34]  H C Charles,et al.  Impact of APOE in mild cognitive impairment , 2004, Neurology.

[35]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[36]  Yaakov Stern,et al.  Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E , 2001, Neurobiology of Aging.

[37]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[38]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[39]  S. Resnick,et al.  Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype , 2000, Neurology.

[40]  P. Scheltens,et al.  Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias , 1999 .

[41]  P. Scheltens,et al.  Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. , 1999, Archives of neurology.

[42]  L. S. Steijns,et al.  [Apolipoprotein E polymorphism and Alzheimer disease]. , 1996, Tijdschrift voor gerontologie en geriatrie.

[43]  D. Galasko,et al.  Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. , 1995, Annals of neurology.

[44]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.